TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00058214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01906359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Native palm olein (IV56)
Description: Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemically interesterified palm olein (IV56)
Description: Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil
Description: Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Study: NCT01731899

Intervention type: DRUG
Intervention: agomelatine
Description: Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
Study: NCT03050697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONI® Modular Toric Intraocular Lens
Description: Two-component system consisting of a base and a separate toric optic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract extraction with intraocular lens (IOL) implantation
Description: Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
Study: NCT03473522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise Therapy
Description: Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
Study: NCT03797924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receive ICBN with ropivacaine
Description: ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No ICBN block
Description: The site of injection will be prepped with tinted chlorhexidine
Study: NCT01930812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NaF PET/CT Imaging
Description: Diagnostic imaging test that is considered investigational

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 99mTc-medronate whole body bone scan with SPECT
Description: 99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
Study: NCT03475628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
Study: NCT03418168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
Study: NCT00396331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
Study: NCT03051139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component LTVV implementation strategy
Description: Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
Study: NCT01058551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder Insertion
Description: Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
Study: NCT01045915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: naked DNA coding for protein AMEP
Description: 2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
Study: NCT03678779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: $5 grocery gift card
Study: NCT01152437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Patients receive cetuximab intravenously, once a week, every week
Study: NCT04570384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Citrulline
Description: L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
Study: NCT02192957

Intervention type: DEVICE
Group type: OTHER
Intervention: Lifepak 20E Defibrillator, Licence No: 61944
Description: Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion
Study: NCT03249818

Intervention type: DEVICE
Group type: OTHER
Intervention: HITT device
Description: Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
Study: NCT01359124

Intervention type: BEHAVIORAL
Intervention: Exercise Cycle
Description: Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.

Intervention type: BEHAVIORAL
Intervention: Land-based Treadmill
Description: Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.

Intervention type: BEHAVIORAL
Intervention: Water-based Treadmill
Description: Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
Study: NCT03518021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone, intranasal
Description: Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, intranasal
Description: Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone, intramuscular
Description: Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, intramuscular
Description: Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
Study: NCT03988621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ViCCY
Description: Virtual Caregiver Coach for You
Study: NCT01404234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
Study: NCT03895073

Intervention type: OTHER
Intervention: healthy volunteers
Description: the questionnaire has been assessed by both groups, healthy and heart failure

Intervention type: OTHER
Intervention: healthy volunteers
Description: the questionnaire has been assessed by both groups, healthy and heart failure
Study: NCT01480778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG+EE2
Description: Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nordette
Description: Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
Study: NCT02217969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic alert to SLUScore increase
Description: Treat hypotension to minimize further progression of the SLUScore
Study: NCT01074931

Intervention type: DRUG
Intervention: Lopinavir/ritonavir (Kaletra)
Description: Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study.
Study: NCT04466891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: Administered intravenously
Study: NCT02735291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
Study: NCT02301442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + behaviour change intervention
Description: In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + control education
Description: The control group will receive exercise and education components. The exercise intervention includes aerobic \& strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers \& exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
Study: NCT01456715

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil vaccine, Immunogenicity, Booster dose.
Description: Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix Vaccine, Immunogenicity, Booster Dose.
Description: Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
Study: NCT03145649

Intervention type: OTHER
Intervention: Dietary therapy or insulin injection
Study: NCT06290297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation VRRS
Description: Telerehabilitation programs delivered at home, aiming to improve cognitive, motor and/or speech-language skills, through VRRS - Khymeia or Niurion devices. Such technologies are equipped with a wide library of activities to be performed also with the use of peripheral sensors. A one-shot assessment is also proposed to children admitted to institutes adhering to the project in order to understand the feasibility of the use of such devices. Ad hoc feasibility questionnaire are administered at the end of the one shot session and after the home training to the main stakeholders (children, families, clinicians)
Study: NCT00734240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via 2 hour IV infusion, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via 2 hour IV infusion, 6 doses over 22 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via SC injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via SC injection, 6 doses over 22 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via 2 hour IV infusion, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via 2 hour IV infusion, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via SC injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via SC injection, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via 2 hour IV infusion, 6 doses over 22 days
Study: NCT01930812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Sodium Fluoride (NaF)
Description: A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
Study: NCT02446353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES / Megace
Description: Sequences of administered drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES / Megace
Description: Sequences of administered drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES / Megace
Description: Sequences of administered drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES / Megace
Description: Sequences of administered drugs
Study: NCT02979730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Lab Test
Description: For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED Point of Care Test
Description: For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
Study: NCT01367301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Undergo HDR brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04585217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)
Description: Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)
Description: Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality.
Study: NCT01672437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth and parent preparation
Description: 4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
Study: NCT00796601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esreboxetine
Description: Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated tablets (0 mg esreboxetine), once daily for 6 months
Study: NCT00734240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via 2 hour IV infusion, 6 doses over 22 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via SC injection, 6 doses over 22 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via SC injection, 6 doses over 22 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
Study: NCT05181748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma
Description: Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
Study: NCT03901807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
Description: TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
Study: NCT00893048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone, 60 mg, one time at time of diagnosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo